6 November 2024 in Epidemiology and Vaccinal Prevention
The problem of biological safety is extremely relevant today for all countries of the world because of the real and potential threats caused by biological agents that are dangerous to public health and the environment. Modern microorganisms are becoming increasingly aggressive towards humans, as clearly demonstrated by the COVID-19 pandemic, which has affected all aspects of people's lives and exposed the vulnerability of the healthcare system. According to the Decree of the President of the Russian Federation «On the Fundamentals of the State policy of the Russian Federation in the field of chemical and biological safety for the period up to 2025 and beyond» and the Federal Law «On Biological Safety in the Russian Federation», the main objectives of state policy are to reduce the risks of negative effects of biological factors on the population and the environment. Antimicrobial resistance, the emergence of new infections and the overcoming of interspecific barriers by microorganisms are of particular concern. Infectious disease agents with epidemic potential, such as Ebola, Zika, Marburg, Lassa, MERS-CoV and SARS-CoV viruses, continue to pose a high threat. To counteract new biological threats, Russia has created a scientific concept of future biosafety, focusing on the development of genomic epidemiological surveillance, digital transformation and mobile technologies. Effective management of epidemic processes requires constant monitoring of genetic changes in infectious agents and prompt response to new threats, which allows the VGARus platform created in Russia to monitor virus mutations. Thus, genomic epidemiological surveillance is becoming a key element of ensuring biological safety and scientific and technological development in Russia.
6 September 2024 in Epidemiology and Vaccinal Prevention
Relevance. The high infectivity and mutagenicity of SARS-CoV-2, combined with the relative short duration of the immune response, means that the problem of controlling the incidence of COVID-19 will continue to be relevant. Aims. To plan anti-epidemic measures, you need to know the quantitative value of the basic reproductive number (R0), however, the available methods for estimating the R0 made it possible to estimate it only for the initial version of SARS-CoV-2. In this regard, the task was set to develop a method for estimating R0 for current pathogen variants based on the rate of change from one variant to another, including both viruses and bacteria. Materials and methods. A modification of the SIR model for two variants of SARS-CoV-2 and actual data on the incidence of COVID-19 and the results of sequencing the virus SARS-CoV-2 isolated in Moscow are used. Results. It was found that for the SARS-CoV-2 Delta variant R0 was about 10, and for the current Omicron variants it exceeds 30. Discussion. In contrast to existing methods, the proposed method allows one to estimate R0 in the context of anti-epidemic measures, as well as by the dynamics of morbidity in a population with a collective immune status, taking into account the typical structure of the circulating SARS-CoV-2. Conclusion. The proposed method makes it possible to estimate the change in the basic reproductive number of the SARS-CoV-2 based on the rate of displacement of one variant by another
2 January 2026 in Epidemiology and Vaccinal Prevention
Relevance Aims . Development of an algorithm for calculating the epidemiological and economic effectiveness of Mass PCR testing for SARS-CoV-2 infection in the Russian Federation during 2020–2022. Materials and methods. Rospotrebnadzor Statistical form №1035 «Monitoring the number of cases of coronavirus infection, including community-acquired pneumonia, and deaths» for 2020- 2022. Circulating variants SARS-CoV-2 is obtained from VGARus. PCR-testing results for SARS-CoV-2 infection were obtained from the Russian information system «SOLAR», demographic data - from Rosstat (Federal State Statistics Service). The base reproductive number (R0) used in the study was: Wuhan + Alpha – 2.74, Delta – 5.02, Omicron SARS-CoV-2 – 9.5. The average cost of one completed case of a new coronavirus infection (COVID-19) in hospitalization or outpatient treatment for the Russian Federation: asymptomatic and mild in the outpatient option – 28,000 rubles, moderate illness – 122,000 rubles. Severe, critical and moderate illness – 216,000 rubles. Statistical analysis was performed using standard methods of variation statistics. SciPy, Pandas, Statsmodels were used for statistical processing of the results obtained and data visualization. Results . During the period 2020–2022, mass PCR testing for SARS-CoV-2 infections in Russian Federation has prevented an estimated between 4.83 million to 1.58 billion COVID-19 cases. The total damage averted from COVID-19 for 2020 to 2022 through mass PCR-testing of the population in the Russian Federation and subsequent isolation, amounted to 3,013 to 10,323 billion rubles. Conclusion . Mass PCR-testing for SARS-CoV-2 infection is highly cost-effective and has reduced the averted damage from COVID-19 by 1.8–3.8 times in 2020-2022.